Cargando…
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours
Losoxantrone is a DNA intercalator that was developed with the potential to replace anthracyclines. The recommended single agent dose of losoxantrone is 50 mg m(−2) every 3 weeks. We conducted a phase I study of losoxantrone and a fixed dose of cyclophosphamide on a q3 weekly schedule. Forty-nine pa...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375276/ https://www.ncbi.nlm.nih.gov/pubmed/11870533 http://dx.doi.org/10.1038/sj.bjc.6600123 |